NHS Digital has launched the new Data Security and Protection toolkit, replacing the previous Information Governance toolkit, to help keep patient information safe.
The Data Security and Protection toolkit is an online self-assessment tool that enables health and social care organisations to measure and publish their performance against the National Data Guardian’s ten data security standards.
All organisations that have access to NHS patient data and systems – including NHS Trusts, primary care and social care providers and commercial third parties – must complete the Toolkit to provide assurance that they are practising good data security and that personal information is handled correctly.
Reductions to the price of three multiple sclerosis (MS) drugs mean NICE is now able to recommend them for routine NHS funding.
NICE has published draft guidance recommending interferon beta-1b (Extavia, Novartis), glatiramer acetate (Copaxone, Teva UK Ltd), and interferon beta-1a (Avonex, Biogen Idec Ltd, and Rebif, Merck Serono Ltd) – as treatment options for people with a type of MS called relapsing-remitting MS.
At the NHS England public board meeting on 30 November 2017, NHS England and the National Institute for Health Research (NIHR) published a joint statement that committed to 12 actions to support and apply research in the NHS. Between November 2017 and February 2018, NHS England, working with the Department of Health and Social Care, the Health Research Authority and the NIHR launched a public consultation on proposals to better manage excess treatment costs and eliminate delays and further improve commercial clinical research set-up and reporting. The response document summarises the feedback received and outlines our next steps for implementation.